首页 | 本学科首页   官方微博 | 高级检索  
检索        

二甲双胍与美沙拉嗪在小鼠结肠炎中的疗效比较
引用本文:邓钧,曾丽珊,刘乐,陈烨.二甲双胍与美沙拉嗪在小鼠结肠炎中的疗效比较[J].新医学,2021,52(8):566-571.
作者姓名:邓钧  曾丽珊  刘乐  陈烨
作者单位:510655 广州,中山大学附属第六医院消化内科(邓钧);511400 广州,广州番禺中心医院消化内科(曾丽珊);510080 广州,南方医科大学南方医院消化内科(刘乐,陈烨)
基金项目:国家自然科学基金(81770529)
摘    要:目的 探讨二甲双胍与美沙拉嗪在治疗小鼠结肠炎中的疗效差异性。方法 选取6 ~ 8周龄的C57BL/6雄性小鼠32只,随机分为Control组、硫酸葡聚糖(DSS)组、DSS+美沙拉嗪组、DSS+二甲双胍组,每组8只。Control组小鼠自由饮用高压灭菌双蒸水,并每日予0.2 ml 磷酸盐缓冲液(PBS)灌胃。采用3%DSS诱导C57BL/6雄性小鼠结肠炎模型。DSS组小鼠自由饮用3%DSS溶液,每日予0.2 ml PBS灌胃,DSS+美沙拉嗪组、DSS+二甲双胍组自由饮用3%DSS溶液,予100 mg/(kg·d) 的美沙拉嗪或100 mg/(kg·d) 二甲双胍灌胃。评估各组小鼠体质量变化、结肠长度、疾病活动指数、组织病理学改变及肠道炎症因子表达情况。结果 与DSS组相比,DSS+二甲双胍与DSS+美沙拉嗪组均可降低小鼠结肠炎所致的体质量丢失、疾病活动度评分、组织病理学评分及肠道炎症因子表达水平(P均< 0.05),但DSS+二甲双胍组与DSS+美沙拉嗪组上述指标比较差异均无统计学意义(P均> 0.05)。结论 二甲双胍可以减轻DSS诱导的小鼠结肠炎,其疗效不亚于美沙拉嗪。

关 键 词:结肠炎  二甲双胍  美沙拉嗪  疗效  
收稿时间:2021-03-05

Comparison of efficacy between metformin and mesalazine in treatment of experimental colitis in mouse models
Deng Jun,Zeng Lishan,Liu Le,Chen Ye.Comparison of efficacy between metformin and mesalazine in treatment of experimental colitis in mouse models[J].New Chinese Medicine,2021,52(8):566-571.
Authors:Deng Jun  Zeng Lishan  Liu Le  Chen Ye
Institution:Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China
Abstract:Objective To compare the efficacy between metformin and mesalazine in the treatment of experimental colitis in mouse models. Methods Thirty-two C57BL/6 male mice aged 6-8 weeks were randomly divided into the control, dextran sulphate sodium (DSS), DSS+mesalazine and DSS+metformin groups, with 8 animals in each group. In the control group, the animals were given ad libitum access to autoclaved double-distilled water and oral gavage of 0.2 ml PBS daily. C57BL/6 male mouse models were induced by 3% DSS. In the DSS group, the mice were given ad libitum access to 3% DSS and oral gavage of 0.2 ml PBS daily. In the DSS+mesalazine and DSS+metformin groups, the animals were given ad libitum access to 3% DSS, and oral gavage of 100 mg/(kg·d) mesalazine or metformin. The body weight, colon length, disease activity index (DAI), histopathological changes and the expression levels of pro-inflammatory cytokines were evaluated in each group. Results Compared with the DSS group, mice treated with DSS+metformin or DSS+mesalazine experienced significantly less body weight loss,lower DAI scores, lower histopathological scores and lower expression levels of pro-inflammatory cytokines(all P < 0.05). No significant difference was noted between the metformin and mesalazine groups(all P > 0.05). Conclusion Metformin can ameliorate DSS-induced experimental colitis in mice, which yields equivalent efficacy to that of mesalazine.
Keywords:Colitis  Metformin  Mesalazine  Efficacy  
点击此处可从《新医学》浏览原始摘要信息
点击此处可从《新医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号